Core Insights - Agilent Technologies reported fourth-quarter fiscal 2024 earnings of 1.46pershare,exceedingtheZacksConsensusEstimateby3.61.70 billion, surpassing the Zacks Consensus Estimate by 1.67%, with a reported increase of 0.8% year-over-year and a core basis decrease of 0.3% [18] Revenue Segments - Agilent operates through three reporting segments: Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG) [4] - LSAG generated 833million,accountingfor49426 million, representing 25% of total revenues, with a 5% growth year-over-year [5] - DGG revenues decreased 1% year-over-year to 442million,accountingfor26109 million, down 6% from the prior year [7] - Selling, general and administrative (SG&A) expenses rose slightly to 362million,a1.41.33 billion, down from 1.78billionasofJuly31,2024[10]−Long−termdebtincreasedto3.35 billion from 2.14billioninthepriorquarter[11]−Cashflowfromoperatingactivitieswas481 million in the fourth quarter, compared to 452millioninthepreviousquarter[26]GuidanceandOutlook−ForQ1fiscal2025,non−GAAPearningspershareareexpectedtobebetween1.25 and 1.28[12]−Fiscal2025non−GAAPearningspershareguidancewasrevisedto5.54-5.61from5.21-5.25[13]−Revenueguidanceforfiscal2025wasupdatedfrom6.45-6.50billionto6.79-$6.87 billion, implying a reported increase of 4.3-5.5% [28]